All patients | 1009 (100.0) | 1577 | 693 (68.7) |
Baseline FVC % pred <50% | 144 (14.3) | 213 | 91 (63.2) |
Concomitant immunosuppressive therapies | 272 (27.0) | 436 | 190 (69.9) |
Concomitant other therapies for IPF | 586 (58.1) | 938 | 419 (71.5) |
Pirfenidone use for conditions other than IPF | 3 (0.3) | 2 | 2 (66.7) |
Predisposing conditions for liver disease | 190 (18.8) | 246 | 120 (63.2) |
QT prolongation | 14 (1.4) | 18 | 11 (78.6) |
Underlying specific cardiac events | 176 (17.4) | 326 | 126 (71.6) |
Underlying hepatic disease | 43 (4.3) | 83 | 31 (72.1) |
Underlying other forms of pulmonary disease | 271 (26.9) | 421 | 181 (66.8) |
Warfarin use | 48 (4.8) | 76 | 34 (70.8) |
Paediatric patients | 0 (0.0) | | |
Secondary causes of pulmonary fibrosis | 0 (0.0) | | |